All Articles

JCPenney is offering $10 for a gas receipt. A simple gimmick, or a shrewd strategic move to drive traffic and data in a brutal retail landscape?

A landmark acquisition pairs a powerful AI engine with deep human expertise, signaling a new era for how brands connect with diverse audiences.

Ouster's new BABA-compliant lidar sensors gain a critical edge, positioning the company to capture a major share of U.S. infrastructure spending.

For patients with inoperable brain tumors, new diagnostic guidelines offer hope by validating CSF profiling, a disruptive technology poised to redefine care.

A $50M Air Force contract for AEVEX isn't just another defense deal. It's a bet on tech that works without GPS, shaping a new US military strategy.

With $135M from Salesforce and a vision from Chamath Palihapitiya, 8090 aims to revolutionize enterprise software with human-governed AI agents.

PowerBank secures $4.2M from new institutional investors, earmarking funds for critical U.S. federal projects and military energy independence.

Skyhawk Therapeutics' oral drug SKY-0515 not only stabilized but appeared to improve key metrics in Huntington's patients, a profound shift in a field long awaiting a breakthrough.

Private equity giant CD&R is deploying capital differently, investing $4.5M in five diverse NYC non-profits. It's a strategic play beyond simple charity.

Facing a disconnect between its growing operations and its market price, Sucro Limited is reviewing its strategy. What does this move reveal about the future of sugar?

xTool's new O1 Omni Printer combines four industrial printing methods into one desktop unit, aiming to revolutionize production for small businesses and creators.

OrangeX's shift to WOWX is more than a name change. It's a high-stakes gamble on compliance, hype, and a new trading philosophy. But will it work?

Kite Realty Group is executing a sophisticated financial maneuver, refinancing debt to cut costs while buying back shares—a dual strategy that signals confidence.

Kennametal's appointment of Amanda Cole as CHRO isn't just a leadership shuffle. It is a calculated response to the seismic shifts reshaping the industrial sector.

A new study reveals how Salipro Biotech's platform makes 'undruggable' membrane proteins accessible, a milestone that could reshape pharmaceutical R&D.

A landmark deal with Croatia's Orqa not only builds Canada's drone industry but also makes it the first non-EU nation to join Europe's SAFE defense initiative.

Using advanced airborne geophysics, Eminent Gold has pinpointed key drill targets in Nevada, de-risking a major program. Is this the start of a new gold trend?

Cytonics completes a key safety trial for its novel osteoarthritis drug, CYT-108. But the real story is a masterclass in strategic innovation.

Eminent Gold is betting on advanced geophysics to unlock a new Carlin-style gold system in Nevada. New data reveals prime targets for a massive drill program.

GRAIL's revolutionary cancer test failed a key trial, wiping out billions and sparking a fraud lawsuit. A deep dive into the fallout for investors and science.